Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
The announcement underscores the company's progress toward bringing an off-the-shelf treatment for knee cartilage lesions to a market where currently no such option is available in the United States. According to the company, GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. The product is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The company's lead product, GelrinC, is CE Mark-approved and represents a significant advancement in orthopedic treatment.
The training initiative is expected to begin at Humanitas Research Hospital in Milan, with additional sessions planned across Europe. For more information on the full press release, visit https://ibn.fm/QOWWK.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company's SEC filings. All parties undertake no duty to update this information unless required by law.
